Best Marketing Grants for Nonprofits in Ohio

The FY26 Parkinson’s Research Program Investigator-Initiated Research Award supports innovative, multidisciplinary research projects aimed at advancing the understanding and treatment of Parkinson’s disease. The award encourages collaboration among multiple principal investigators, requiring preliminary data and allowing clinical trials to enhance research outcomes. This initiative is vital for fostering impactful discoveries within the four specified focus areas of the program, ultimately improving patient care and management.

The FY26 Parkinson’s Research Program (PRP) Early Investigator Research Award supports early-career researchers in Parkinson’s disease (PD) research. It offers two funding levels: Level 1 for fellows requiring a Mentor and Level 2 for independent investigators. The PI must show potential in PD research, with Level 1 emphasizing mentorship and Level 2 needing preliminary data. Research must align with one of the four FY26 PRP Focus Areas, excluding clinical trials.

The DOW Combat Readiness – Medical Research Program's FY26 Translational Research Award supports innovative research aimed at improving trauma care outcomes. This program emphasizes hypothesis-driven studies that can transition promising technologies into practical solutions for enhancing casualty survivability. Applicants must provide preliminary data and utilize validated animal models, with a focus on projects that meet a minimum technology readiness level of 4, ensuring a mature translational research effort.

The CAO Legislative Crisis Grant, funded by the National Education Association Staff Organization, is designed to support affiliates in creating and refining student-centered initiatives. Grants can be utilized for contract campaigns, new program development, or enhancing existing practices to improve sustainable learning conditions. This opportunity is exclusive to affiliates, ensuring a focused approach to advocacy and collective bargaining efforts that benefit students.

The National Institute of Allergy and Infectious Diseases (NIAID) is advancing research on immune tolerance through its Collaborative Network. This program aims to clarify the mechanisms of immune tolerance and develop interventions for related diseases, including transplant rejection and autoimmune disorders. Key objectives include conducting clinical trials on tolerogenic strategies and refining immune assays. This initiative is supported by regulations under the Public Health Service Act, ensuring a structured approach to improving patient outcomes.

The Translational Transplantation Tolerance Cooperative Study Group, supported by the National Institute of Allergy and Infectious Diseases, aims to advance transplant tolerance strategies that promote long-term graft survival without lifelong immunosuppression. This initiative focuses on developing, optimizing, and evaluating methods to induce immune tolerance in allogeneic transplants through collaborative efforts across multiple centers, utilizing translationally relevant models to ensure effective outcomes.

The National Institute of Allergy and Infectious Diseases (NIAID) is advancing organ transplantation outcomes through the Clinical Trials in Organ Transplantation in Children and Adults (CTOT-CA) program. This initiative supports multicenter clinical trials and mechanistic studies related to heart, lung, kidney, liver, and intestinal transplants, as well as non-hematopoietic cellular transplantation. By exploring immune mechanisms and innovative therapies, the program aims to enhance the success and efficacy of organ transplantation.

GBA1 Parkinson's Disease Research Catalyst Program

The GBA1-PD Research Catalyst Program seeks to build a deeper, globally integrated understanding of GBA1-associated Parkinson’s disease by aligning efforts across geographies and maximizing the value of shared datasets and research assets. Funding will support hypothesis- driven projects with an emphasis on integrative, cross-cohort analyses and the systematic characterization and standardization of models to enable broad use by the research community.

Funding

Duration: 12 to 24 months

Award Amount: Up to $300,000. Requested support should be commensurate with work proposed.

These budgets include direct and indirect costs. For academic and for-profit institutions, no more than 15% or 10%, respectively, may go to indirect costs. 

Accelerating the Development of Combined CGM–Pump Devices

A combined continuous glucose monitor (CGM) and insulin pump device represents an innovative approach to simplifying diabetes management by integrating two essential technologies into a single device. This approach has the potential to improve quality of life for people with type 1 diabetes (T1D) by reducing the burden associated with wearing and managing multiple devices.

Despite this promise, the development of combined CGM–pump devices presents technical and commercialization challenges. These include the need for further advances in device compatibility and lifespan, system reliability, and scalable manufacturing, while maintaining affordability and broadaccessibility. In addition, a potential insulin dilution effect may require adjustment of the CGM algorithm.

Breakthrough T1D invites applications for research and development projects that address key technical, clinical, and translational challenges related to combined CGM–pump devices, with the goal of accelerating their development and improving outcomes for people living with T1D.

In response to this announcement, applications may request up to a total of $900,000 USD for up to three years. 

AD Osherman Scholarship

Benefiting first-generation students in Texas.

Funding

Four (4) scholarships awarded out:

• $3,500 for students pursuing a 4-year degree
• $2,500 for students pursuing a 2-year degree

One-time award. Previous recipients may reapply as long as all eligibility requirements are met.

Camillo Family Scholarship 

Benefiting dependents of Camillo Properties, Camcorp Entities, or LCI Services employees.

The Camillo Family Scholarship was created to provide dependents of employees of Camillo Companies (Camillo Holdings, LCI Services, Legend Homes, Millmark Capital, and SimplyHome) with scholarships to further their education.

This is a renewable scholarship, meaning recipients can renew the award and claim up to 4 years of funding if they meet the GPA and enrollment requirements and complete the renewal application for each academic year they plan to be enrolled.

Multiple scholarships awarded for the 2026-27 academic year. Award amount varies by college/degree type:

• 4-Year College/University - The scholarship is comprised of up to four annual awards of $5,000, for a total award of up to $20,000. The four annual awards may be received over a period of up to five years.
• 2-Year College/Trade School - The scholarship award is comprised of up to two annual awards of $2,500, for a total award of up to $5,000. The two annual awards may be received over a period of up to three years.

What can the scholarship be used for?

The scholarship will be mailed directly to the student's college to be used towards tuition, required academic fees, and/or book expenses. 

Scholarship funding cannot be distributed directly to the student. 

Transportation Assistance Grant

The Transportation Assistance Grant program was established to help members of the MS community remain as independent as possible, and ensure all people with MS have the transportation necessary to get the best medical care.

The program provides funding for reasonable paratransit fees. In partnership with Lyft and Uber, the program can also provide funding for transportation to and from appointments for MS care, limited to neurologist visits and infusion centers, at no cost to the person with MS.

The Innovations for Healthy Living program invites eligible U.S. small businesses to apply for SBIR grants aimed at improving minority health and eliminating health disparities. The initiative encourages innovative proposals for effective, affordable, and culturally acceptable solutions. Key deadlines for applications span from June 2024 to December 2026, with optional Letters of Intent recommended 30 days prior to submission. This funding opportunity supports projects that address health challenges faced by underserved populations.

The Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42) program invites small business concerns to develop innovative technologies aimed at enhancing minority health and addressing health disparities. This initiative emphasizes the creation of effective, affordable, and culturally acceptable solutions for NIH-defined populations. Key deadlines for applications span from June 2024 to December 2026, with optional Letters of Intent encouraged 30 days prior to submission.

The T.E.A.L. Research Grant supports innovative ovarian cancer research initiatives aligned with the mission of the Tell Every Amazing Lady About Ovarian Cancer Foundation. Designed for researchers affiliated with 501(c)3 not-for-profit institutions in the U.S., the grant aims to enhance women's health awareness and education regarding ovarian cancer. While the application period for 2025 is currently closed, interested parties should anticipate further updates in spring 2026.

The MNAF Linda Knauff Clinical Practice Project Grant supports Minnesota Nurses Association members in conducting research that aligns with MNA's organizational goals. It promotes best practices through literature reviews, workgroup convening, policy development, and quality improvement initiatives. Applicants must be MNA members engaged in direct patient care, complete their projects within two years, and submit periodic reports. Preference is given to first-time applicants whose projects meet quality standards.

The MNA Associate Member Scholarships provide financial assistance to MNA associate members who are typically undergraduate nursing students. Offered by the Minnesota Nurses Association Foundation, these scholarships aim to support the professional development and educational goals of nursing students, contributing to the advancement of the nursing profession and ensuring access to quality healthcare for all. Eligible candidates include MNA members, their dependents, and veterans, fostering a commitment to nursing excellence.

The Mary Eliza Mahoney Scholarships, offered by the Minnesota Nurses Association Foundation (MNAF), provide financial support to nursing students, members of healthcare unions, their dependents, and veterans. Each scholarship awards $2,500 per semester for a maximum of four semesters, totaling up to $10,000. This initiative aims to enhance nursing education and promote the professional growth of future nurses, ensuring access to quality healthcare for all.

Who We Are

Community foundations began nationally in 1914 and are publicly-supported, 501(c)(3) philanthropic organizations that hold, administer, invest and make grants from both endowed and non-endowed funds established by individuals, families and others. They were designed to be simple, flexible, convenient, tax-wise, cost-effective and perpetual charitable vehicles.  

Our Community Foundation was established in Roanoke in 1988. With our growth, we expanded into the Martinsville/Henry County area in 2005. Today, we administer many hundreds of named endowment funds ranging in size from a minimum of $10,000 to millions of dollars. To date, donors have also committed very significant resources to the Foundation through future estate gifts.

Information for Scholarship Seekers

Community Foundation Serving Western Virginia, the region’s community foundation, administers a variety of scholarships to reward and assist capable and deserving students based on the criteria established by the fund donors.

Specifics of the Foundation’s scholarship program may be subject to change from time to time. If you have any questions or need additional information, please contact the Foundation at (276) 656-6223.

Ashby C. and John T. Pinkard Scholarship Fund

 Fund provides higher education scholarships to deserving young men and women.

The AES Infrastructure Grant, offered by the American Epilepsy Society, provides up to $50,000 to support the development of national or international multicenter research programs. This funding is intended for organizational planning sessions, infrastructure development, and pilot projects, facilitating future investments from other organizations. These grants are available annually in the spring, enabling researchers to enhance their collaborative efforts.

Agog Open Call: Climate Futures + Immersive Media

This open call supports immersive media projects that help people better understand and respond to climate challenges and imagine what a better world could be.

We are looking for projects that use immersive technologies—including smart glasses, augmented reality, spatial sound, and mixed reality—to create more engaging, experiential forms of climate storytelling and civic participation.

The open call will support projects across a range of stages and formats, from early ideas to more developed work. What matters most is a compelling story or experience, a clear sense of purpose, and a thoughtful approach to bringing the work to life.

Grants may be awarded in denominations ranging from $25,000 to $200,000. In addition to funding, selected projects may receive mentorship, advisor support, and opportunities for partnership and distribution.

About Pfizer Grants

Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pre-clinical Investigation of anti-TFPI-mediated Rebalancing Mechanisms in Non-Hemophilic Bleeding Disorders

There remains a scientific gap in understanding of the role of anti-TFPImediated hemostatic rebalancing in the context of inherited or non-hemophilic bleeding disorders. This competitive grant program encourages competitive submissions focsed on generating preclinical/foundational data exploring the therapeutic potential and mechanisms of TFPI modulation in bleeding disorders other than hemophilia.

Project Types and Area of Interest

Potential applicants are encouraged to identify and address preclinical/basic science data generation for TFPI modulation/rebalancing in their local setting. This may include:

• Rare bleeding disorders which arise from deficiencies in different clotting factors or pathway components but converge on a common functional endpoint which is an impaired thrombin generation (e.g., Factor II, Factor V, Factor VII, Factor X and Factor XI deficiencies, as well as von Willebrand disease).
• Other diseases such as Glanzmann's thrombasthenia (GT) that have a distinct pathophysiological mechanism.
• Other rare bleeding disorders whose mechanisms are not well understood (e.g., Bleeding Disorder of Unknown Cause, BDUC).

Myasthenia Gravis Rare Disease Network (MGNet)

The Myasthenia Gravis Rare Disease Network (MGNet) is a consortium of academic medical centers partnering with the Myasthenia Gravis Foundation of America and Conquer MG as well as collaborators in other research groups and industry. We are working together to enhance therapeutic development for this rare disease.

Diseases Studied

Myasthenia Gravis (MG) and its subtypes:

• Early-onset acetylcholine receptor (AChR) antibody (Ab) positive MG, which primarily affects women
• Late-onset AChR Ab positive MG with a disease bias towards men
• Paraneoplastic thymoma-associated MG
• Muscle specific kinase (MuSK) Ab positive
• AChR/MuSK antibody negative MG

Goals, Mission, & Vision

The goal of MGNet is to advance therapeutic development. To do so we have four specific aims:

• Improve the tools scientists and doctors have for performing clinical trials through rigorous monitoring of patients over time and evaluate better measures of how patients are doing.
• Identify objective measures (biomarkers) to show how the disease is responding to treatment and better predict treatment response or side effects, to improve the design of clinical trials and care of patients in clinical practice.
• Enhance the education of young investigators focusing their careers on rare diseases and specifically MG.
• Improve the awareness of scientists, physicians, and the public regarding the unique needs of patients with MG through training of clinician scientists and engagement of the patient and scientific communities in clinical research and therapeutic development.

Pilot and Feasibility Grants

Objectives

MGNet, a NIH-funded Rare Diseases Clinical Research Consortium (RDCRC) in partnership with the Myasthenia Gravis Foundation of America and Conquer MG, is seeking proposals for highly innovative investigations in early stages of development.

The priorities of the Pilot Grant Program are:

• Identification treatment responsive biomarkers
• Assess clinical measures and improve that enhance clinical trial readiness
• Evaluation of therapeutic interventions for one or more of the five distinct sub-types of MG

Pilot studies must be designed to access the resources of MGNet and focused on clinical and translational research, including fulfilling the definition of clinical and translational research and exclusion of animal studies.

Funding

The MGNet expects to fund up to two grants, each at a level of $75,000 (IDCs will be limited to 10% and included in the $75,000). Projects will be funded for 12 months. Selection among the applications received will be based on the recommendations of a review committee. A grant may be renewed for an additional one year with approval of interim report by the same review process and availability of funds. Demonstration of fulfillment of initial aims and justification for additional funding will be required. The request will be required a minimum of three months prior to the initial funding period completion.

Myasthenia Gravis Rare Disease Network (MGNet)

The Myasthenia Gravis Rare Disease Network (MGNet) is a consortium of academic medical centers partnering with the Myasthenia Gravis Foundation of America and Conquer MG as well as collaborators in other research groups and industry. We are working together to enhance therapeutic development for this rare disease.

Diseases Studied

Myasthenia Gravis (MG) and its subtypes:

• Early-onset acetylcholine receptor (AChR) antibody (Ab) positive MG, which primarily affects women
• Late-onset AChR Ab positive MG with a disease bias towards men
• Paraneoplastic thymoma-associated MG
• Muscle specific kinase (MuSK) Ab positive
• AChR/MuSK antibody negative MG

Goals, Mission, & Vision

The goal of MGNet is to advance therapeutic development. To do so we have four specific aims:

• Improve the tools scientists and doctors have for performing clinical trials through rigorous monitoring of patients over time and evaluate better measures of how patients are doing.
• Identify objective measures (biomarkers) to show how the disease is responding to treatment and better predict treatment response or side effects, to improve the design of clinical trials and care of patients in clinical practice.
• Enhance the education of young investigators focusing their careers on rare diseases and specifically MG.
• Improve the awareness of scientists, physicians, and the public regarding the unique needs of patients with MG through training of clinician scientists and engagement of the patient and scientific communities in clinical research and therapeutic development.

Scholar Awards

Objectives

There is a critical need for investigators prepared to conduct clinical and translational research in myasthenia gravis (MG). The MGNet Scholar Program provides individualized training and mentorship in one of two tracks, Clinical Research or Biomarker Development Research.

Award Description

The MGNet Scholar Program provides mentored research training to prepare Scholars for an independent research career in the field of MG. The MGNet Scholar Program is 1 year in duration and selected Scholars receive up to $100,000 to support salary, research costs and didactics with potential for renewal. The program will provide an additional $3,000 to travel to MGNet sites to learn specific skills and/or to scientific meeting(s) to present the results of their research. If available for renewal, the program requires approval after interim report and is contingent on demonstration of adequate progress on the research and career development plan. Indirect costs are not allowed. Scholars are encouraged to transition to NIH (e.g., K award), departmental, or private foundation support for their research and further career development.Research must constitute at least 50% of each Scholar’s professional effort. Each Scholar must form a 2-3-member advisory committee to include a primary mentor, an additional clinician investigator or collaborator, and a MGNet faculty sponsor. The advisory committee will meet with the Scholar at least quarterly to review progress and each Scholar will develop an individual academic career development plan and renew it with the committee at least every 6 months.

The National Multiple Sclerosis Society offers Postdoctoral Fellowships to support innovative research aimed at advancing the understanding and treatment of multiple sclerosis. These fellowships are designed for promising researchers holding advanced degrees, providing funding for training that enhances their ability to conduct impactful studies. The Society prioritizes applications that align with high-priority research questions outlined in its Pathways to Cures Roadmap, emphasizing the importance of diverse methodologies and engagement with underserved populations.

The Dalsemer Interstitial Lung Disease Award, funded by the American Lung Association, provides $50,000 per year for two years to support junior investigators researching interstitial lung disease. This award aims to foster independence in early-career scientists while building on the Association's 120-year legacy of improving lung health through innovative research and advocacy efforts, ultimately enhancing the lives of those affected by lung disease.

HCLTech Grant Edition II focuses on impactful climate action by investing $5 million over five years to support NGOs in the Americas. This initiative aims to enhance sustainable projects that align with the 17 Sustainable Development Goals (SDGs). With a history of significant contributions in India, HCLTech is committed to achieving net-zero emissions by 2040 and fostering innovative solutions to address pressing climate challenges. The grant encourages collaboration and aims to transform communities through effective climate action.